Weight Loss for Kidney Stones
Trial Summary
What is the purpose of this trial?
This protocol seeks to determine if weight reduction with the Optifast VLCD program leads to reduced contribution of endogenous oxalate synthesis and dietary oxalate absorption to the urinary oxalate pool in obese calcium oxalate stone formers.
Will I have to stop taking my current medications?
You will need to stop taking weight-loss medications and certain medications for stone prevention, like diuretics, potassium citrate, allopurinol, febuxostat, and calcium, nutritional, or herbal supplements, for 14 days before and during the study.
What data supports the effectiveness of the treatment Optifast VLCD Program for weight loss in kidney stone patients?
Is the Optifast VLCD Program safe for humans?
How does the Optifast VLCD Program treatment differ from other treatments for kidney stones?
The Optifast VLCD Program is a very low-calorie diet designed for weight loss, which may help reduce the risk of kidney stones by addressing obesity, a known risk factor. Unlike surgical options like bariatric surgery, which can increase kidney stone risk, this diet focuses on controlled calorie intake to manage weight without altering the body's metabolism in ways that could increase stone formation.3461112
Research Team
Dean G Assimos, MD
Principal Investigator
University of Alabama at Birmingham
Eligibility Criteria
This trial is for obese individuals with a BMI over 35 who have had calcium oxalate kidney stones but no stone issues in the last 3 months. Participants must not have diabetes, severe dyslipidemia, or recent surgery and should be willing to follow specific dietary guidelines and avoid certain medications.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Controlled Diet Phase
Participants consume an eucaloric, ultra-low oxalate controlled diet for 6 days, including dietary equilibration and oxalate/sucralose oral load
Weight Loss Program
Participants undergo a 14-week Optifast VLCD® Program to induce weight loss
Post-Weight Loss Controlled Diet Phase
Participants repeat the low oxalate controlled diet and dietary/sucralose oral load study to observe changes after weight loss
Follow-up
Participants are monitored for safety and effectiveness after the weight loss program
Treatment Details
Interventions
- Optifast VLCD Program
Optifast VLCD Program is already approved in United States, European Union for the following indications:
- Dietary management of obesity
- Preparation for bariatric surgery
- Dietary management of obesity
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of Alabama at Birmingham
Lead Sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Collaborator
University of Texas Southwestern Medical Center
Collaborator